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phospholamban which are also targets of the Ca2+/Calmodulin Kinase II (CaMKII). 
Any disregulation in the β-adrenergic pathway can lead to cardiac arrhythmias. 
Multiple cyclic nucleotide phosphodiesterases (PDEs) regulate local concentrations 
of cAMP, among which the PDE4 family plays an important role. The aim of this 
study is to investigate the proarrythmic effects of PDE4 inhibition and evaluate the 
relative contribution of PKA and CaMKII in this mechanism. Action potentials (AP) 
were recorded at a frequency of 1 Hz in isolated adult rat ventricular myocytes using 
the patch clamp technique. Application of the non selective β-AR agonist Isoprenaline 
(Iso, 1 nM) increased the occurrence of delayed afterdepolarizations (DADs) recorded 
during 10 s after the cessation of electrical stimulation from 0.5±0.2 DAD/10s (n=25) 
to 2.1±0.4 DADs/10s (n=25; p<0.001). This effect of Iso was potentiated to 3.1±0.4 
DADs/10s (n=25; p<0.01 versus Iso alone) by the PDE4 inhibitor Ro20-1724 (Ro, 
10 μM). These DADs correlated with spontaneous calcium release events (SCRs) 
recorded with an IonOptix system in myocytes loaded with Fura-2AM (5 μM). The 
SCRs appeared upon Iso application (1 nM) and their incidence increased from 
1.6±0.4 SCRs/10s (n=19) in Iso alone to 4.2±0.5 SCRs/10s (n=24; p<0.001) when 
PDE4 was concomitantly inhibited. The SCRs observed in the presence of Iso+Ro 
were abolished in cells preincubated with the PKA inhibitor H-89 (10 μM) (n=5; 
p<0.01) and their occurrence diminished by 50% when CaMKII was inhibited by 
10 μM KN-93 (n=14; p<0.01). The inactive KN92 (10 μM) compound had no effect 
on SCRs. These results show that upon β-AR stimulation, PDE4 inhibition promotes 
DADs due to SCRs through both PKA and CaMKII activation.
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Role of caveolae in agonists-induced pulmonary arterial contraction
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We previously showed that serotonin (5-HT) produces superoxide anion (O2
·-) 
in the intrapulmonary artery (IPA) smooth muscle. Then, O2
·- passes through the 
myoendothelial gap junction (connexin (Cx) 43) to decrease the bioavailability 
of endothelial NO and hence reinforce IPA vasoreactivity (PLoS ONE, 2009, 4, 
e6432). Since Cx 43 is (1) known to be involved in the contraction to 5-HT and not 
to endothelin-1 (ET-1), phenylephrine (Phe) and high potassium solutions (KCl) and 
(2) known to be colocalized with caveolin-1 (Cav-1), main protein of caveolae, we 
studied the role of caveolae in the contraction to these various well known contractile 
agonists of rat IPA. 
Immunofl uorescent labelling on transversal sections of rat IPA revealed that, 
unlike 5-HT1B and ETB receptors, both 5-HT2A and α1D receptors (Phe receptors) 
colocalized with Cx 43. 5-HT2A receptors and Cx 43 also colocalized with cav-1. 
Transmission electron microscopy evidenced the presence of myoendothelial gap 
junctions and numerous caveolae in endothelial and smooth muscle cells from rat 
IPA. Caveolae lipid rafts were removed with methyl-β-cyclodextrin (7 mM) and 
isometric contraction was then recorded on rings from rat IPA by using organ bath 
system. Such treatment decreased contraction to 5-HT and Phe (inhibition of 58 and 
20 % respectively – n=12-15) whereas the contraction to ET-1 and KCl were not 
signifi cantly modifi ed (n=14–26). 
Altogether, we demonstrated that cav-1 and/or Cx 43 are colocalized with 5-HT2A 
and α1D receptors which are known to be involved in the contraction to 5-HT and 
Phe respectively. Moreover, our results showed that caveolae removal is functionally 
important in some agonists-induced contraction of rat IPA (namely 5-HT and Phe 
but not ET-1 and KCl). 
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Specifi cty of CACNA1C promoter regulation by mineralocorticoid signaling 
in cardiac myocytes
Gaëlle Auguste, Gema Ruiz Hurtado, Eric Morel, Ana Maria Gomez, Jean-Pierre 
Bénitah
Inserm U769, Châtenay-Malabry, France
The crucial role of aldosterone action in the heart in promoting life threatening 
arrhythmias has been demonstrated by the benefi cial use of Mineralocorticoid Receptor 
(MR) blockers. However, molecular mechanisms involved remain to be characterized. 
We have accumulated evidences that modulation of L-type Ca2+ channel is a central 
factor in the cardiac action of mineralocorticoid signaling. We analyze whether Aldo 
through the MR, has a direct action on the main subunit, the Cav1.2 encoded by the 
CaCNA1C gene expression, based on the presence of putative hormone response 
elements (GRE) in the regulatory region of this gene. Rat ventricular myocytes in primary 
culture were transfected with a plasmid construct containing the 5’-fl anking region 
of CACNA1C that drives a reporter gene. We observed a dose- and time-dependent 
activation of CACNA1C promoter by Aldo, blunted in presence of MR antagonists, 
and mimicked by a constitutively active MR (ΔhMR5,6). Mutation of the putative GRE 
abolished Aldo and ΔhMR5,6 response, whereas the effect of glucocorticoid receptor 
agonist, dexamethasone, seems to be preserve. Using quantitative real time RT-PCR, 
we found that Aldo increases the Cav1.2 mRNA in time and dependant manner. 
We showed functionality of cardiac MR following nucleo-cytoplasmic traffi cking 
after aldo treatment at once by immunocytochemistry and by confocal microscopy. 
Interestingly, transfected neonatal rat atrial myocytes did not respond to aldo whereas 
ΔhMR5,6 stimulates CaCNA1C promoter activity. In addition, transactivation of a 
plasmid construct that contain an artifi cial promoter with two highly conserved GRE 
driven reporter gene, showed lowest affi nity for aldo than CACNA1C promoter. 
Those results point out a specifi c ventricular action of Aldo through cardiac MR 
transactivation on CACNA1C promoter, leading us to propose Cav1.2 as a primary 
MR target, with subsequent molecular and functional consequences that could lead 
to MR-related cardiac dysfunction.
197
Phosphodiesterase type 4 inhibition increases delayed afterdepolarizations 
upon β-adrenergic stimulation in cardiac myocytes: Role of protein kinase 
A and Ca2+/Calmodulin kinase II
Pierre Bobin, Rodolphe Fischmeister, Grégoire Vandecasteele, Jérôme Leroy
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France
β-adrenergic receptor (β-AR) stimulation increases cardiac function by increasing 
cAMP levels and activating Protein Kinase A (PKA). PKA enhances Ca2+-induced 
Ca2+-release by phosphorylating L-type Ca2+ channels, ryanodine receptors and 
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Background: Aldosterone (Aldo) is involved in cardiovascular and renal alterations 
associated with heart failure (HF) development, but the mechanisms have remained 
unclear. Galectin-3 (Gal-3), a β-galactoside-binding lectin, is increased in HF. We 
here investigated whether Gal-3 is involved in Aldo-induced cardiovascular and renal 
fi brosis and dysfunction.
Methods and Results: Wistar rats were treated with Aldo-salt combined with 
spironolactone or modifi ed citrus pectin (MCP), a Gal-3 inhibitor, for 3 weeks. 
Hypertensive Aldo-treated rats exhibited increased left ventricular end diastolic pressure 
and -dP/dt compared with controls. Cardiac index, left ventricular cross sectional area 
and wall thickness were increased in Aldo-salt-treated rats. Myocardial expression 
of molecular markers assessing fi brosis as well as Gal-3 levels were also augmented 
by Aldo-salt. At the vascular level (aorta), media thickness, collagen, fi bronectin 
and Gal-3 expressions were increased by Aldo-salt treatment. Aldo-salt-treated rats 
presented increased glomerular and tubulo-interstitial fi brosis accompanied by renal 
epithelial-mesenchymal transition, urinary and serum neutrophile gelatinase-associated 
lipocalin (NGAL) and microalbuminuria/creatininuria ratio, paralleled with an enhanced 
Gal-3 levels. Spironolactone or MCP treatment reversed all the above cardiac, vascular 
and renal effects. In another set of experiment, a 3 weeks Aldo infusion increased 
cardiac, vascular and renal Gal-3 and collagen type I expressions in Wild type but 
not in Gal-3 knockout mice.
Conclusions: In experimental hyperaldosteronism the Gal-3 increase was associated 
with cardiac, vascular and renal fi brosis and dysfunction that are prevented with Gal-3 
pharmacological inhibition (MCP) as well as with Gal-3 knockout. These data suggest 
a key role for Gal-3 in cardiac, vascular and renal remodelling and dysfunction induced 
by Aldo that could be used as a biotarget for specifi c pharmacological interventions.
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CD146 mediates melanoma cell extravasation and VEGF-induced transen-
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CD146 is an adhesion molecule expressed by both melanoma and endothelial 
cells and thus is well positioned to control melanoma dissemination. Nevertheless, 
the involvement of tumor microenvironment CD146 in melanoma metastasis has 
never been analyzed. To investigate whether host CD146 mediates the extravasation 
of melanoma cells across the endothelium, we generated CD146 KO mice. We 
demonstrated that host CD146 did not affect melanoma growth or tumor angiogenesis 
but promoted hematogenous melanoma dissemination to the lung. Accordingly, 
the survival of CD146-defi cient mice was markedly prolonged during melanoma 
metastasis. Interestingly, vascular endothelial growth factor (VEGF) -induced vascular 
permeability was signifi cantly decreased in CD146 KO mice. Consistent with an 
endothelial cell defi ciency, VEGF- induced transendothelial migration of melanoma 
cells was signifi cantly reduced across CD146 KO lung microvascular endothelial cells 
(LMECs). CD146 defi ciency did not affect the expression of the VEGF/VEGF receptor 
system but altered VEGF-induced focal adhesion kinase (FAK) protein expression 
and activation. We propose a novel mechanism involving the VEGF/CD146/FAK 
interactome network in melanoma extravasation across the vessel barrier that identifi es 
CD146-targeted therapy as a potential strategy for the treatment of melanoma metastasis.
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Vascular effects of ranolazine involve antagonism of both Nav channels and 
alpha1-adrenergic receptors
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Background and aims: Ranolazine (Ranexa) is a novel anti-anginal and anti-
ischemic drug used for treatment of patients with chronic stable angina. This drug is 
reported to predominantly reduce the Na-dependent Ca2+ overload via the inhibition of 
the late Na+ currents (I
NaL) that occurs in cardiomyocytes during ischemia. Nav channels 
are present in arteries and we previously showed that ranolazine exerts a vasodilatory 
effect on rat aorta in part through their inhibition. In the present study, we evidenced 
an additional mechanism of action implicated in the vascular effects of ranolazine.
Methodology/Principal fi ndings: We studied variations in isometric tension 
of rat aortic rings in response to ranolazine in the presence of various vasoconstric-
tors. Ranolazine induced a vasorelaxation only when contraction was triggered by 
phenylephrine (not with endothelin, vasopressin and angiotensin II). This effect was 
dose dependent (EC50=8.4±1.3 nM) and occurred independently of the endothelium. 
Prior application of rnolazine (5 to 20 μM) prevented the contraction induced by 
phenylephrine. Using Bodipy-FL prazosin we observed that ranolazine antagonized the 
binding of this ligand to the alpha1-adrenergic receptor on rat aorta. This antagonism 
was further confi rmed on cultured smooth muscle cells with Ca2+imaging using fura-2. 
Phenylephrine (1 μM) increased intracellular Ca2+, which was prevented by ranolazine 
(20 μM) as also observed with the alpha1-adrenergic antagonist prazosin (10 μM). 
Conclusion: Ranolazine, a Na+ channel blocker is also an alpha1-adrenergic 
antagonist. The vasodilatory effects observed on rat aorta involve both I
NaL inhibition 
and alpha1-adrenergic antagonism. These interactions may be implicated in the 
anti-anginal properties of ranolazine.
